Ahmed Eraky @ahmederaky

SUO Fellow at Mountsinai Manhattan, NY Joined June 2009

Tweets

3K
Followers

599
Following

864
Likes

7K

Toni Choueiri, MD @DrChoueiri

3 weeks ago

JUST IN: IMvigor011 in muscle-invasive bladder cancer (MIBC) hits both DFS & OS with PD-L1 inhibitor Atezolizumab in ctDNA+ population. Major news for Precision Oncology in adjuvant Solid Cancers! @NateraGenetics @tompowles1 @Roche natera.com/company/news/i…

2 71 158 25K 32

Download Image

Ahmed Eraky @ahmederaky

a month ago

I was lucky to attend the SP symposium and learn from SP experts. To stay ahead of the curve, it’s crucial to embrace innovation and leverage technology to maximize the benefits for our patients.

Michael Stifelman @mdstifelman

a month ago

I was lucky to attend the SP symposium and learn from SP experts. To stay ahead of the curve, it’s crucial to embrace innovation and leverage technology to maximize the benefits for our patients.

2 9 47 3K 16

0 0 1 190 0

Ahmed Eraky @ahmederaky

2 months ago

🚨 New in @NatRevUrol : Proud to co-first author a comprehensive review on the molecular & therapeutic landscape of non–clear cell renal carcinoma (nccRCC) — from MET-driven pRCC to SMARCB1-deficient RMC. 🔗 nature.com/articles/s4158… #KidneyCancer #UroOnc #RCC @MehrazinMD

1 2 17 891 2

Emre Yekedüz @yekeduz_emre

2 months ago

🚨A fantastic review for non-clear cell renal cell carcinoma! in @NatRevUrol 👉Time to tailor, not generalize: 🔬 Genotype-driven subtyping (e.g. MET, FH, TSC-mTOR, ALK, MITF, SMARCB1) enables precision therapy. 💊 Cabozantinib & savolitinib show promise in MET-driven tumors.…